LANTHEUS HOLDINGS INC. - COMMON STOCK

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

27 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Lantheus Appoints Vivian Yao as Chief Human Resources Officer

01 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Lantheus Announces PYLARIFY AI™ is Now Available

29 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022

22 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings

17 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference

16 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results

04 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Lantheus Holdings to Present at Upcoming Investor Conferences

28 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time

21 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer

13 Sep 2021 08:00:03 By Nasdaq GlobeNewswire